Cargando…

Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis

OBJECTIVE: To assess the efficacy and tolerance of tocilizumab (TCZ) in giant cell arteritis (GCA) patients over 80. METHOD: GCA patients over 80 years old from the French Study Group for Large Vessel Vasculitis register who received TCZ were analyzed. RESULTS: Twenty-one GCA patients (median age 84...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Boysson, Hubert, Le Besnerais, Maelle, Blaison, Félix, Daumas, Aurélie, Jarrot, Pierre-André, Perrin, François, Tieulié, Nathalie, Maria, Alexandre, Duffau, Pierre, Gombert, Bruno, Samson, Maxime, Espitia, Olivier, Lambert, Marc, Mékinian, Arsène, Aouba, Achille
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132404/ https://www.ncbi.nlm.nih.gov/pubmed/34011407 http://dx.doi.org/10.1186/s13075-021-02529-4

Ejemplares similares

An Updated Review of Cardiovascular Events in Giant Cell Arteritis
por: de Boysson, Hubert, et al.
Publicado: (2022)

[(18)F]FDG PET-MR characterization of aortitis in the IL1rn(−/−) mouse model of giant-cell arteritis
por: Deshayes, Samuel, et al.
Publicado: (2023)

Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
por: Mekinian, Arsène, et al.
Publicado: (2023)

Giant-cell arteritis without cranial manifestations: Working diagnosis of a distinct disease pattern
por: de Boysson, Hubert, et al.
Publicado: (2016)

Whole‐Country and Regional Incidences of Giant Cell Arteritis in French Continental and Overseas Territories: A 7‐Year Nationwide Database Analysis
por: Guittet, Lydia, et al.
Publicado: (2022)

Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial
por: Mekinian, Arsene, et al.
Publicado: (2020)

Impact of Glucocorticoid Cumulative Doses in a Real-Life Cohort of Patients Affected by Giant Cell Arteritis
por: Castan, Paul, et al.
Publicado: (2022)

(18)F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis: A multicenter cohort of 130 patients
por: de Boysson, Hubert, et al.
Publicado: (2016)

Evolution of the Therapeutic Management of Giant Cell Arteritis: Analysis of Real-Life Practices over Two Timeframes (2014–2017 and 2018–2020)
por: de Boysson, Hubert, et al.
Publicado: (2023)

Anakinra for patients with COVID-19
por: Martin-Silva, Nicolas, et al.
Publicado: (2020)

Large-vessel involvement is predictive of multiple relapses in giant cell arteritis
por: de Mornac, Donatienne, et al.
Publicado: (2021)

Impact of Giant Cell Arteritis and Its Treatment on the Patient's Quality of Life: A Single-Center Self-Assessment Study
por: de Boysson, Hubert, et al.
Publicado: (2021)

Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis
por: Samson, Maxime, et al.
Publicado: (2021)

Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
por: Laurent, Charlotte, et al.
Publicado: (2021)

Chronic intestinal pseudo-obstruction with dilated biliary tract as a spectrum of stiff person syndrome in a nondiabetic patient
por: Nguyen, Alexandre, et al.
Publicado: (2019)

Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013)

Benchmarking tocilizumab use for giant cell arteritis
por: Conway, Richard, et al.
Publicado: (2022)

Tocilizumab for faster and safer remission of Takayasu’s arteritis
por: Liao, Hua, et al.
Publicado: (2022)

Comment on: Benchmarking tocilizumab use for giant cell arteritis
por: Janagan, Shalini, et al.
Publicado: (2022)

Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study)
por: Mahr, Alfred, et al.
Publicado: (2021)

Profile of tocilizumab and its potential in the treatment of giant cell arteritis
por: Mollan, Susan Patricia, et al.
Publicado: (2018)

Vision loss in patients with giant cell arteritis treated with tocilizumab
por: Amsler, Jennifer, et al.
Publicado: (2021)

Giant Cell Arteritis With Chronic Bronchitis Successfully Treated With Tocilizumab
por: Ohta, Ryuichi, et al.
Publicado: (2023)

Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis
por: Seitz, Luca, et al.
Publicado: (2021)

Tocilizumab for relapsing and remitting giant cell arteritis: a case series
por: Saha, Pratyasha, et al.
Publicado: (2022)

Utility and safety of tocilizumab in Takayasu arteritis with severe heart failure and muscle wasting
por: Yano, Toshiyuki, et al.
Publicado: (2019)

Effectiveness of Tocilizumab in juvenile patients with refractory Takayasu arteritis: Two case reports
por: Asano, Tomoyuki, et al.
Publicado: (2020)

Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review
por: Li, Haiyan, et al.
Publicado: (2021)

Perioperative Management of Takayasu Arteritis for Cardiac Surgery in a Patient Treated With Tocilizumab
por: Arita, Yoh, et al.
Publicado: (2020)

Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?
por: Farinango, Michelle, et al.
Publicado: (2022)

Safe use of tocilizumab in pregnant women with Takayasu arteritis: three case studies
por: Konagai, Nao, et al.
Publicado: (2023)

Correction: Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
Publicado: (2023)

Risk factors for symptomatic vascular events in giant cell arteritis: a study of 254 patients with large-vessel imaging at diagnosis
por: de Mornac, Donatienne, et al.
Publicado: (2021)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

55. A case for continuing tocilizumab beyond 12 months in giant cell arteritis?
por: Ming, Caroline, et al.
Publicado: (2019)

Anti-interleukin-6 (tocilizumab) therapy in Takayasu’s arteritis: a real life experience
por: KILIÇ, Levent, et al.
Publicado: (2020)

Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
por: Butryn, Michaela, et al.
Publicado: (2021)

Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
por: Loricera, Javier, et al.
Publicado: (2022)

Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis
por: Kang, Limei, et al.
Publicado: (2023)

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis
por: Matza, Mark A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i5qt9q6nkf07oatkudnh6u0trf